Recursion to release Q3 2026 results and update on REC-4881 for FAP in Nov webinar

Recursion Pharmaceuticals will announce its third quarter 2026 financial results on November 2, 2026, followed by a webinar on November 3 featuring updates on its drug candidate REC-4881 for familial adenomatous polyposis (FAP). The webinar will include presentations of clinical data, a panel of key opinion leaders discussing the unmet needs in FAP, and patient advocates sharing experiences. This event precedes an expected regulatory update on REC-4881 by the end of the year, highlighting Recursion's ongoing efforts in AI-driven drug discovery for rare diseases. Investors and the public can participate via live streams and submit questions in advance.

Recursion Pharmaceuticals Inc (RXRX) trades at USD 3.80 on Pluang as of Oct 27, 2026 03:11 WIB, up 2.70% in the last day. The stock shows balanced investor interest with 50% sell and 50% buy orders. Its market cap stands at $2.00 billion, reflecting steady engagement ahead of the upcoming financial results and webinar.